Posts

Posted on

Catapult Learning Announces New Free Diversity and Equity Webinar Series for Educators

Culturally Responsive Classrooms: Strategies for Identifying & Eliminating Systemic Bias While Celebrating Student Diversity & Promoting Equity

CAMDEN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Catapult Learning, a provider of intervention programs for students and professional development solutions for teachers in both public and nonpublic K-12 schools, today announced a free three-part webinar series, Culturally Responsive Classrooms: Strategies for Identifying & Eliminating Systemic Bias While Celebrating Student Diversity & Promoting Equity, in response to racial inequities impacting teaching and student learning experiences.

The professional development webinars will examine how racism and implicit bias can influence teachers’ expectations of students and their ability to build meaningful relationships and create inclusive classroom and school cultures. Each of the webinars – Understanding Structural Racism and Its Impact on Students, Promoting Equity Through Culturally Responsive Teaching Practices,and Culturally Affirming Social-Emotional Learning Practices – will feature experts and cover topics such as structural racism and its impact on students, promoting equity through culturally responsive teaching practices and culturally affirming social-emotional learning.

The first

webinar

in the
series,

Understanding Structural Racism and Its Impact on Students


,

takes place on Thur
sday,
December 3
, 2020 at
noon
E
S
T.

“Implicit bias and systemic racism exist in classrooms and schools throughout our country. Although these biases are unintentional, they still have a negative impact that affects learning, engagement, achievement, and students’ social and emotional well-being,” said Devon Wible, vice president of academics, Catapult Learning. “We’re looking forward to connecting with educators to discuss strategies to recognize implicit bias and how to plan and create learning environments that celebrate diversity, promote equity, and allow children to be themselves within a culturally responsive classroom.”

The
12
/
3
webinar
, hosted by
public health, education, and inclusion strategist Shirley Torho
,
presents an opportunity for participants to:

  • Define key terms, including race, racism, systemic racism, and implicit/explicit bias
  • Explore ways that systemic racism is built into society, making it difficult to recognize
  • Identify ways in which biases create blind spots that impact the way people see and respond to others
  • Apply strategies to recognize implicit bias, build cultural competence, and promote equity in schools, classrooms, and districts

The webinars are available to school administrators and leaders. The series will take place on Thursday, December 3, 2020, Wednesday, January 27, 2021 and Thursday, March 25, 2021.

To register for the December 3, 2020 webinar Understanding Structural Racism and Its Impact on Students, click here.

About Catapult Learning


Catapult Learning
, a division of FullBloom, provides intervention programs for students and professional development solutions for teachers in both public and nonpublic K-12 schools. Our 5,000 educators deliver evidence-based programs that include student instruction, family support services, and professional development designed to help teachers’ efforts to successfully integrate proven practices into the classroom. Executed by a team of experienced coaches, our professional development services strengthen the capacity of teachers and leaders to raise and sustain student achievement, improving education and overall quality of life. Intervention programs support struggling learners with instruction tailored to the unique needs of each student. Across the country, Catapult Learning partners with 500+ school districts, including 18 of the 20 largest, to produce positive outcomes that promote academic and professional growth. Additionally, Catapult has strong partnerships in place with the U.S. Department of Defense Education Activity and the Center on Teaching & Learning at the University of Oregon. Learn more at CatapultLearning.com.



Press Contact
Jennifer Leckstrom
RoseComm for Catapult Learning
(215) 681-0770
[email protected]

Posted on

Alaska Airlines further modernizes fleet with 13 new leased 737-9 MAX aircraft

PR Newswire

SEATTLE, Nov. 23, 2020 /PRNewswire/ — Alaska Airlines announced a transaction today that continues the optimization of its mainline fleet. As part of the agreement, Alaska will sell 10 Airbus A320s to Air Lease Corporation, and subsequently lease 13 new Boeing 737-9 MAX aircraft from them. The 13 737-9 MAX aircraft will be delivered from fourth quarter 2021 through 2022. Alaska will lease the A320s back from Air Lease for a short period of time after the transaction closes.

“Alaska’s relationship with Steve dates back to the early 1980s and we’re thrilled to work with him and ALC on an agreement that will enhance our fleet and advance our environmental, operational and financial performance,” said Brad Tilden, Alaska Air Group chairman and CEO. “We found an opportunity to sell 10 planes that are not in our long-term plans and replace them with 13 of the most efficient narrow-body aircraft available.”

“We are honored and pleased to renew our long association and partnership with our friends at Alaska Airlines,” said Steven F. Udvar-Házy, executive chairman of Air Lease Corporation. “These leased Boeing 737-9 aircraft from ALC will fill an important role on Alaska’s diverse route network, bringing the most technologically advanced and environmentally attractive aircraft type into Alaska’s fleet, just in time as we expect the airline industry will undergo a sustainable recovery starting in 2021.”

The MAX aircraft are 20 percent more fuel efficient and generate 20 percent less carbon emissions per seat than the A320s they will replace. The aircraft is also able to fly 600 miles farther than Alaska’s current A320, which opens the possibility of additional nonstop routes and new destinations.

The 13 leased aircraft are in addition to the 32 MAX Alaska currently has on order with Boeing – five of which are expected to be flying by summer 2021. Alaska will begin flying the 737-9 MAX in March 2021. Read more about how Alaska will prepare to fly its first MAX at alaskaair.com/737MAX.

After permanently parking all A319s and some A320s earlier this summer, this deal leaves Alaska Airlines with 39 A320s in the operating fleet along with 10 A321neos.

Alaska Airlines and its regional partners serve more than 115 destinations across the United States and North America. The airline provides essential air service for our guests along with moving crucial cargo shipments, while emphasizing Next-Level Care. Alaska is known for low fares, award-winning customer service and sustainability efforts. Guests can earn and redeem miles on flights to more than 800 destinations worldwide with Alaska and its Global Partners. On March 31, 2021, Alaska will officially become a member of the oneworld global alliance. Learn more about Alaska at newsroom.alaskaair.com and blog.alaskaair.com. Alaska Airlines and Horizon Air are subsidiaries of Alaska Air Group (NYSE: ALK).

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alaska-airlines-further-modernizes-fleet-with-13-new-leased-737-9-max-aircraft-301178636.html

SOURCE Alaska Airlines

Posted on

SoCalGas and SDG&E Announce Groundbreaking Hydrogen Blending Demonstration Program to Help Reduce Carbon Emissions

Program is first step toward establishing a statewide hydrogen injection standard

PR Newswire

LOS ANGELES, Nov. 23, 2020 /PRNewswire/ — As part of their commitment to support California’s climate goals and their mission to become the cleanest, safest and most innovative energy companies in America, Southern California Gas Co. (SoCalGas) and San Diego Gas and Electric (SDG&E) today announced the creation of a Hydrogen Blending Demonstration Program. This program would be the first in California and among the first in the nation.   

Blending hydrogen with natural gas is part of a multi-pronged strategy both utilities – subsidiaries of Sempra Energy – are undertaking to decarbonize their natural gas grid. The vision is to leverage surplus renewable electricity generated in the middle of the day to produce green hydrogen, which then can be injected into the natural gas grid for storage and use. Power-to-gas technology is being developed to do just that. SoCalGas, in partnership with the National Fuel Cell Research Center, and University of California Irvine, is leading the way in developing this technology, launching the first power-to-gas demonstration project in the United States in 2015. Hydrogen blending is another important milestone for providing the clean fuel needed to achieve California’s climate goals while maintaining an affordable, resilient and reliable energy system.

When adopted by the California Public Utilities Commission (CPUC), the demonstration program will provide an understanding of how to safely incorporate hydrogen, a zero-emission fuel, into the gas grid. This is the first step toward the establishment of a statewide hydrogen injection standard.

“Our California-based utility businesses are helping build California’s 21st century energy system through deliberate investments in hydrogen, renewable natural gas, fuel cells, and carbon capture and storage,” said Kevin Sagara, group president for Sempra Energy and chairman of SoCalGas and San Diego Gas & Electric. “This hydrogen blending program is a key milestone in our efforts to decarbonize our energy system, while delivering affordable and reliable energy to 22 million California customers.”

“Green hydrogen is a game-changer, not only for our power and energy needs, but also for our industrial and transportation sectors,” said Sen. Nancy Skinner (D-Berkeley). “And green hydrogen can support existing, good-paying jobs as our state and communities take steps to transition to a zero-carbon economy.”

“Today’s announcement is an exciting development for California’s emerging renewable hydrogen market,” said Bill Zobel, Executive Director of the California Hydrogen Business Council. “The Hydrogen Blending Demonstration Program will help the public understand that renewable hydrogen is important and a valuable tool for our carbon neutral future.”

SoCalGas and SDG&E are planning multiple hydrogen blending projects throughout their respective service territories. The first proposed project will blend hydrogen into an isolated section of primarily polyethylene (PE) plastic distribution system in SoCalGas’ service territory. The initial hydrogen blend level is planned at 1% and may increase to as much as an industry-leading 20%.  

SoCalGas expects to choose the location of the initial project in early 2021.

Subsequent projects are scheduled in SDG&E’s service territory and will build upon the knowledge learned in the first demonstration. This includes blending hydrogen into an isolated section of mixed plastic and steel natural gas distribution system, and an isolated steel pipeline demonstration.

In addition to these hydrogen blending projects, SDG&E announced in October that it intends to pilot two hydrogen projects by 2022 as part its comprehensive sustainability strategy to advance carbon neutrality. These two projects would use a combination of technologies such as renewable resources, electrolysis and fuel cells to demonstrate increased system resiliency, long-duration storage, power-to-gas hydrogen fuel blending, and vehicle hydrogen fueling, among other applications.

SoCalGas is helping to build California’s 21st century energy system with investments in hydrogen, renewable natural gas, fuel cells and carbon capture and storage. These innovations will help the utility decarbonize its pipeline system. Last year, SoCalGas set a goal to deliver 5% renewable natural gas (RNG), produced from organic waste, to its core customers by 2022 and 20% by 2030. SoCalGas and SDG&E are also seeking CPUC approval of a program that will offer customers the option to purchase RNG as part of their natural gas service. The program is set to be voted on by the CPUC in December.

The Hydrogen Blending Demonstration Program is part of a joint application filed with the California Public Utilities Commission (CPUC) by SoCalGas, SDG&E, Pacific Gas and Electric (PG&E) and Southwest Gas in accordance with the Biomethane Order Instituting Rulemaking (Biomethane OIR). The filing can be found here.

About SoCalGas
Headquartered in Los Angeles, SoCalGas® is the largest gas distribution utility in the United States. SoCalGas delivers affordable, reliable, clean and increasingly renewable gas service to 21.8 million customers across 24,000 square miles of Central and Southern California, where more than 90 percent of residents use natural gas for heating, hot water, cooking, drying clothes or other uses. Gas delivered through the company’s pipelines also plays a key role in providing electricity to Californians— about 45 percent of electric power generated in the state comes from gas-fired power plants.

SoCalGas’ vision is to be the cleanest gas utility in North America, delivering affordable and increasingly renewable energy to its customers. In support of that vision, SoCalGas is committed to replacing 20 percent of its traditional natural gas supply with renewable natural gas (RNG) by 2030. By developing renewable gas from our state’s abundant organic waste streams, we can help to meet our climate goals sooner, while diversifying our carbon-free energy sources, improving energy resilience and reliability, while also creating additional renewable fuel and jobs for our communities. SoCalGas is also committed to investing in its gas delivery infrastructure while keeping bills affordable for our customers. From 2014 through 2018, the company invested nearly $6.5 billion to upgrade and modernize its pipeline system to enhance safety and reliability. SoCalGas is a subsidiary of Sempra Energy (NYSE: SRE), an energy services holding company based in San Diego. For more information visit socalgas.com/newsroom or connect with SoCalGas on Twitter (@SoCalGas), Instagram (@SoCalGas) and Facebook. 

About SDG&E
SDG&E is an innovative San Diego-based energy company that provides clean, safe and reliable energy to better the lives of the people it serves in San Diego and southern Orange counties. The company is committed to creating a sustainable future by providing its electricity from renewable sources; modernizing natural gas pipelines; accelerating the adoption of electric vehicles; supporting numerous non-profit partners; and, investing in innovative technologies to ensure the reliable operation of the region’s infrastructure for generations to come. SDG&E is a subsidiary of Sempra Energy (NYSE: SRE). For more information, visit SDGEnews.com or connect with SDG&E on Twitter (@SDGE), Instagram (@SDGE) and Facebook.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/socalgas-and-sdge-announce-groundbreaking-hydrogen-blending-demonstration-program-to-help-reduce-carbon-emissions-301178982.html

SOURCE Southern California Gas Company; San Diego Gas & Electric

Posted on

Evolent Health to Participate in Upcoming Investor Conference

PR Newswire

WASHINGTON, Nov. 23, 2020 /PRNewswire/ — Evolent Health, Inc. (NYSE: EVH) (“Evolent”), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Executive Officer and Co-Founder Seth Blackley and Chief Financial Officer John Johnson will participate in an upcoming investor conference.

  • Mr. Blackley and Mr. Johnson will be participating in 1×1 meetings during the 32nd Annual Piper Sandler Healthcare Conference on Wednesday, December 2, 2020. Meetings may be requested exclusively via Piper Sandler.

About Evolent Health


Evolent Health (NYSE: EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance’s Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

Contacts:

Chelsea Griffin

919.817.8045
Investor Relations
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/evolent-health-to-participate-in-upcoming-investor-conference-301178672.html

SOURCE Evolent Health

Posted on

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

PRESS RELEASE

November 23, 2020

  • Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.
  • Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period.
  • Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.
  • Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 2020, at 2:00pm ET / 20.00 CET.

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced positive top-line results from the Phase 2 open-label extension study of Tesomet in patients with hypothalamic obesity (HO). Patients treated with Tesomet for nearly one year (24 week double-blind [DB] followed by 24 week open label extension [OLE]) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. No clinically meaningful differences in heart rate or blood pressure were observed over the course of the trial.

“Hypothalamic obesity is a rare disorder characterized by severe and debilitating obesity that is often complicated by depression, impulse control issues, complicated symptoms from necessary replacement of pituitary hormones, and increased risk of cardiometabolic disorders. There are no treatments specifically approved for HO, and standard weight loss approaches such as surgery, medication and lifestyle counseling are mostly ineffective in this rare disease,” said Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital and Principal Investigator on the Phase 2 study. “The data from this nearly year-long study demonstrate the potential of Tesomet to help manage multiple key symptoms of HO – not only weight gain but also the metabolic dysfunction that can lead to serious diabetic complications. I look forward to the evaluation of Tesomet in further clinical studies.”

“The results of the open-label extension study reinforce the promising profile of Tesomet observed in the placebo-controlled portion of the Phase 2 study in patients with hypothalamic obesity,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development of Saniona. “If approved, Tesomet could be the first treatment designed to address this rare disease. We look forward to continuing our discussions with the FDA and clarifying the path to bring Tesomet to the HO patients who desperately need treatment options.”

Highlights from top-line open-label extension study data include:

  • Safety: The primary endpoint of the study was the overall safety and tolerability of Tesomet in patients with HO. Tesomet was shown to be well-tolerated. Side effects observed in the open-label extension (OLE) period of the study were generally mild and consistent with those observed in the double-blind (DB) period. The most common adverse events included dry mouth, joint pain, headache and dizziness. There were three events of palpitations in the placebo patients who were switched to Tesomet, and none in the group that received Tesomet for the full 48 weeks. There was one serious adverse event related to abdominal pain which spontaneously resolved. There were no clinically meaningful differences in heart rate or blood pressure observed over the nearly year-long study. All 18 patients who entered the OLE study completed it.
  • Bodyweight: As previously reported, treatment with Tesomet led to a statistically significant 6.28% average reduction in bodyweight compared to placebo (p=0.0169) in the 24-week DB period of the study. This reduction was maintained through the 24-week OLE period, with these patients demonstrating a statistically significant 5.96% average reduction in bodyweight at Week 48 (p=0.008 vs baseline). Additionally, patients who received placebo during the DB period and were switched to Tesomet at Week 24 for the OLE period demonstrated a clinically meaningful 4.95% average reduction in bodyweight from baseline to Week 48.
  • Waist circumference: As previously reported, treatment with Tesomet led to a 5.04% reduction in waist circumference compared to placebo (p=0.0519) in the DB period. This reduction was maintained during the OLE period, with these patients demonstrating a 5.07% reduction in waist circumference at Week 48 (p=0.003). Additionally, patients who received placebo during DB period and were switched to Tesomet at Week 24 for the OLE period demonstrated a 2.24% average reduction in waist circumference from baseline to Week 48.
  • Glycemic control: As previously reported, there were two diabetic (T2D) patients who received Tesomet during the DB period, and they showed marked reduction of HbA1c levels (48.8% at Week 24), while no change was seen in normoglycemic patients. These two diabetic patients continued to receive Tesomet during the OLE period, and the reduction in HbA1c was maintained (46.17% at Week 48).

Saniona intends to present and/or publish additional data from this study in an appropriate future peer-reviewed, scientific forum. Additionally, Saniona intends to provide these data to the FDA as part of ongoing communications around plans to ensure that only appropriate patients would receive Tesomet, if approved. Pending this alignment with the FDA, Saniona intends to initiate a Phase 2b study in HO in the first half of 2021.

About the Phase 2 Study

This randomized, double-blind, placebo-controlled Phase 2 study evaluated Tesomet administered daily in patients with HO. The primary endpoint of the study was overall safety and tolerability measured by all safety data collected during the study including recorded adverse events, laboratory data, blood pressure, and heart rate. The secondary efficacy endpoints included bodyweight, waist circumference, glycemic control and other measures. In the double-blind (DB) period of the study, patients received either Tesomet or matching placebo (2:1 randomization) for 24 weeks. A total of 21 patients (13 Tesomet, 8 placebo) were included within the modified intent-to-treat analysis pertaining to the DB period. Top-line results from the DB period were announced in a press release in April 2020.

All 18 patients who completed the DB period of the study were provided the opportunity to receive Tesomet in an open-label extension (OLE) period of the study for an additional 24 weeks. All 18 patients chose to participate in the OLE period, and all patients completed the OLE period. Patients entering the OLE were 83.3% female and on average 44.9 years old, weighing 110.4 kg (243 lbs) with a BMI of 37.2 kg/m2. Further details about the trial can be found at ClinicalTrials.gov.

Webcast

Saniona will host a webcast in which Dr. Feldt-Rasmussen will review the data from this study on Tuesday, 24 November 2020, at 2:00pm ET / 20.00 CET. A live webcast of the presentation can be accessed via: https://edge.media-server.com/mmc/p/33xc2m4t. Subsequently, the event will be archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/.

For more information, please contact

Trista Morrison, Chief Communications Officer. Office + 1 (781) 810-9227. Email: [email protected]

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:00 CET on November 23, 2020.  

About Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with several companies. Saniona is based in Copenhagen, Denmark, and in Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

About Tesomet

Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

About Hypothalamic Obesity (HO)

Hypothalamic obesity (HO) is a rare disorder characterized by intractable weight gain and uncontrollable hunger. Additional symptoms may include memory impairment, attention deficit, impulse control and depression as well as increased risk of cardiovascular and metabolic disorders. Currently, there is no cure for this condition. Treatments used for general weight management such as surgery, medication and lifestyle counseling are often tried in HO, but are mostly ineffective, and there are no medications specifically approved for HO. HO is caused by damage to the hypothalamus, most commonly sustained during surgery to remove a rare, noncancerous tumor called a craniopharyngioma. This tumor can occur at any age, but is most common in children and older adults, creating a burden for both patients and families. HO occurs in approximately one out of every 50,000 to 100,000 people.

 

Attachment



Posted on

Sensient Technologies Corporation to Sell Its Fragrances Business to Symrise

Sensient Technologies Corporation to Sell Its Fragrances Business to Symrise

MILWAUKEE–(BUSINESS WIRE)–
Sensient Technologies Corporation (NYSE: SXT) announced today that it has entered into a definitive agreement to sell its fragrance business to Symrise AG. As part of the transaction, Symrise will be acquiring Sensient’s aroma chemical and fragrance compound production facility and headquarters in Granada, Spain. The Company expects the transaction to be finalized in the first half of 2021, following the receipt of antitrust and regulatory approvals and other customary closing conditions.

Sensient previously announced the divestiture of its inks, yogurt fruit preparations, and fragrances businesses. The Company completed the divestiture of the inks and yogurt fruit preparation businesses earlier this year. Upon completion of the sale of the fragrances business, Sensient will operate with a more focused portfolio of food and pharmaceutical colors, personal care, flavors, extracts and flavor ingredients, and natural ingredients for the food, pharmaceutical, and personal care markets.

“I am pleased that we have been able to execute on our plans to focus our portfolio, and strengthen our position as an advanced solutions provider of specialty ingredients for the food, pharmaceutical, and personal care markets. Our product portfolio provides significant opportunities for Sensient to grow, both organically and inorganically,” said Paul Manning, Sensient’s Chairman, President, and Chief Executive Officer. “We are pleased to be able to transition this business to an industry leading company that is committed to growing and investing in its future. We will lend our full support to Symrise to ensure a successful transition of our employees and customers.”

ABOUT SENSIENT TECHNOLOGIES

Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, cosmetic, and personal care industries. Sensient’s customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world’s best-known brands. Sensient is headquartered in Milwaukee, Wisconsin.

www.sensient.com

ABOUT SYMRISE

Symrise is a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials, as well as functional ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, the pharmaceutical industry and producers of nutritional supplements and pet food. Headquartered in Holzminden, Germany, the Group is represented in more than 100 locations in Europe, Africa, the Middle East, Asia, the United States and Latin America. Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life.

www.symrise.com

Amy Agallar

(414) 347-3706

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Manufacturing Other Manufacturing Cosmetics Retail Chemicals/Plastics

MEDIA:

Logo
Logo
Posted on

Keysight Collaborates With NTU Singapore on Hybrid Vehicle to Everything Communications

Keysight Collaborates With NTU Singapore on Hybrid Vehicle to Everything Communications

Results will help accelerate smart mobility with unified V2X testing

SANTA ROSA, Calif.–(BUSINESS WIRE)–
Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that helps enterprises, service providers and governments accelerate innovation to connect and secure the world, announced a collaboration with Nanyang Technological University, Singapore (NTU Singapore) to develop a transceiver test bench for a hybrid vehicle-to-everything (V2X) communication system.

To fully realize smart mobility, there are several technology challenges including V2X, which is a rapidly emerging technology. V2X technologies include dedicated short-range communication (DSRC) and cellular-V2X (C-V2X). However, a single unified V2X test solution does not currently exist.

NTU Singapore is currently conducting research on a reconfigurable transceiver system specifically for hybrid (DSRC+C-V2X) communication at 5.9 GHz ISM band. This also includes possible extension to the millimeter-wave (mmWave) frequency range using cost-effective complementary metal-oxide semiconductor (CMOS) technology.

Keysight provided NTU with test solutions and capabilities for generating and analyzing both DSRC and C-V2X signals. This included testing and validation requirements for multi-components and system-level specifications in V2X communication standards, as well as 5G signal generation and analysis in the mmWave frequency range and multiple-input and multiple-output (MIMO) mode. As a result, NTU could generate accurate and full characterization of the newly developed transceiver.

Associate Professor Boon Chirn Chye from NTU’s School of Electrical and Electronic Engineering, the lead investigator for the project, said “Keysight’s mmWave expertise and advanced solutions coupled with NTU’s deep expertise in vehicular communications and integrated circuit designs, yielded valuable insights which helped in accelerating the development of hybrid V2X communications that will be tested on the NTU Smart Campus.”

“We are delighted to provide NTU with a wide range of our test and measurement solutions that enable their cutting-edge research,” said EE Huei Sin, senior vice president and president of the Electronic Industrial Solutions Group at Keysight Technologies. “It’s another example of Keysight’s ongoing partnerships with universities to discover the next breakthrough in technology.”

About Keysight Technologies

Keysight Technologies, Inc. (NYSE: KEYS) is a leading technology company that helps enterprises, service providers and governments accelerate innovation to connect and secure the world. Keysight’s solutions optimize networks and bring electronic products to market faster and at a lower cost with offerings from design simulation, to prototype validation, to manufacturing test, to optimizatioin networks and cloud environments. Customers span the worldwide communications ecosystem, aerospace and defense, automotive, energy, semiconductor and general electronics end markets. Keysight generated revenues of $4.2B in fiscal year 2020. More information is available at www.keysight.com.

Additional information about Keysight Technologies is available in the newsroom at https://www.keysight.com/go/news and on Facebook, LinkedIn, Twitter and YouTube.

Geri Lynne LaCombe, Americas/Europe

+1 303 662 4748

[email protected]

Fusako Dohi, Asia

+81 42 660-2162

[email protected]

KEYWORDS: California Singapore United States North America Asia Pacific

INDUSTRY KEYWORDS: Automotive Manufacturing Technology Manufacturing Semiconductor Other Technology Other Manufacturing Audio/Video Engineering Mobile/Wireless Hardware Electronic Design Automation

MEDIA:

Logo
Logo
Posted on

BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm

BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Investors of Class Action and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc.(“Biogen” or the “Company”) (NASDAQ: BIIB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Biogen securities pursuant between October 22, 2019 and November 6, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/biib.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/biib or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Biogen you have until January 12, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

TILE Shareholder Notification: Bronstein, Gewirtz & Grossman, LLC Notifies Interface, Inc. (TILE) Investors of Class Action and Encourages Shareholders to Contact the Firm

TILE Shareholder Notification: Bronstein, Gewirtz & Grossman, LLC Notifies Interface, Inc. (TILE) Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Interface, Inc. (“Interface” or “the Company”) (NASDAQ: TILE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Interface securities pursuant between March 2, 2018 and September 28, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/tile.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (2) consequently, Interface, inter alia, reported artificially inflated income and earnings per share (“EPS”) in 2015 and 2016; (3) Interface and certain of its employees were under investigation by the Securities and Exchange Commission (“SEC”) with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/tileor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Interface you have until January 11, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Rexnord to Participate in Credit Suisse Industrials Conference

Rexnord to Participate in Credit Suisse Industrials Conference

MILWAUKEE–(BUSINESS WIRE)–
Rexnord Corporation (NYSE: RXN) today announced that it will participate in the Credit Suisse Virtual Industrials Conference on December 2, 2018, starting at 8:00 a.m. Eastern.

About Rexnord

Headquartered in Milwaukee, Wisconsin, Rexnord is comprised of two strategic platforms, Process & Motion Control and Water Management, with approximately 6,400 employees worldwide. The Process & Motion Control platform designs, manufactures, markets and services specified, highly-engineered mechanical components used within complex systems. The Water Management platform designs, procures, manufactures and markets products that provide and enhance water quality, safety, flow control and conservation. Additional information about the Company can be found at www.rexnordcorporation.com.

Cautionary Statement on Forward-Looking Statements

Information in this release may involve outlook, expectations, beliefs, plans, intentions, strategies or other statements regarding the future, which are forward-looking statements. These forward-looking statements involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Rexnord Corporation as of the date of the release, and Rexnord Corporation assumes no obligation to update any such forward-looking statements. The statements in this release are not guarantees of future performance, and actual results could differ materially from current expectations. Numerous factors could cause or contribute to such differences. Please refer to “Risk Factors” and “Cautionary Notice Regarding Forward-Looking Statements” in the Company’s Form 10-K for the fiscal year ended March 31, 2020 as well as the Company’s annual, quarterly and current reports filed on Forms 10-K, 10-Q and 8-K from time to time with the Securities and Exchange Commission for a further discussion of the factors and risks associated with the business.

Rexnord Corporation

Rob McCarthy, 414-223-1615

Vice President – Investor Relations

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Architecture Other Energy Energy Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Other Manufacturing Urban Planning Building Systems Landscape Manufacturing

MEDIA:

Logo
Logo